Exploring the pathogenicity of Mycoplasma pneumoniae: Focus on community-acquired respiratory distress syndrome toxins
Authors:
Open Access
- 15 August 2024
- journal article
- research article
- Published by Elsevier in Microbial Pathogenesis
- Vol. 195, 106865
Abstract
No abstract availableKeywords
Funding Information
- National Program for Support of Top-notch Young Professionals (BJ2023089)
- Shanghai Municipal Health and Family Planning Commission (Z202016)
- Wuxi Health and Family Planning Commission
- Natural Science Foundation for Young Scientists of Shanxi Province (BK BK20230189)
- Wuxi Municipal Bureau on Science and Technology (K20221033)
This publication has 46 references indexed in Scilit:
- Insight into the Pathogenic Mechanism of Mycoplasma pneumoniaeCurrent Microbiology, 2022
- Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae InfectionsJAMA Network Open, 2022
- Vaccine using community-acquired respiratory distress syndrome toxin as an antigen against Mycoplasma pneumoniae in miceBiochemical and Biophysical Research Communications, 2022
- Evaluation of the CARDS toxin and its fragment for the serodiagnosis of Mycoplasma pneumoniae infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2021
- Interleukin-23 derived from CD16+ monocytes drives IL-17 secretion by TLR4 pathway in children with mycoplasma pneumoniae pneumoniaLife Sciences, 2020
- Regulating Immunity via ADP-Ribosylation: Therapeutic Implications and BeyondTrends in Immunology, 2019
- An ELISA method to estimate the mono ADP-ribosyltransferase activities: e.g in pertussis toxin and vaccinesAnalytical Biochemistry, 2018
- Incident asthma and Mycoplasma pneumoniae: A nationwide cohort studyJournal of Allergy and Clinical Immunology, 2016
- Mycoplasma pneumoniae in children with acute and refractory asthmaAnnals of Allergy, Asthma & Immunology, 2013
- A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic useVaccine, 2009